Ray Kaczmarek Joins Nanoscope as Chief Technical Officer to Enhance Gene Therapy Manufacturing

Ray Kaczmarek Joins Nanoscope as Chief Technical and Manufacturing Officer

Nanoscope Therapeutics Inc., a clinical-stage biotechnology firm focused on innovative gene therapies for inherited retinal conditions, has announced the appointment of Ray Kaczmarek as its new Chief Technical and Manufacturing Officer. Kaczmarek, a notable figure in gene therapy manufacturing, brings decades of invaluable experience from his extensive career in the pharmaceutical and biotechnology sectors.

A Leader in Gene Therapy Manufacturing

With a robust professional background, Kaczmarek is recognized for his operational leadership and strategic vision in developing gene therapy manufacturing processes. His previous role as Chief Executive Officer at Genezen, a contract development and manufacturing organization (CDMO) specializing in viral vector production, highlights his exceptional expertise in the field. There, he oversaw the organization’s endeavors in process development and GMP manufacturing, driving success in a competitive landscape.

Before joining Genezen, Kaczmarek served as Vice President of GMP Operations at TriLink Biotechnologies. In this capacity, he played a pivotal role in the production of critical components needed for nucleic acid synthesis, which are vital in gene therapy applications. Kaczmarek’s previous leadership stints also include Vice President of Manufacturing and Supply Chain at Pacira Biosciences, and President of Nitto Avecia, where he was instrumental in delivering comprehensive solutions for oligonucleotide production.

Vision for Nanoscope

Sulagna Bhattacharya, Co-founder and CEO of Nanoscope, expressed optimism about Kaczmarek’s appointment, emphasizing that his extensive background will be essential in strengthening the company's operational framework as they progress towards commercializing new gene therapies. “Ray’s expertise will be crucial as we develop the systems and processes necessary for the commercial supply of our therapies aimed at treating debilitating retinal diseases,” she stated.

Nanoscope is currently advancing its gene therapy products, including MCO-010, which has demonstrated positive results in clinical trials. Kaczmarek's leadership will significantly contribute towards the preparation for a Biologics License Application (BLA) submission as the company heads into 2025. His arrival comes at a critical moment for Nanoscope, which is on the verge of entering a new phase of bringing transformative treatment options to patients suffering from inherited retinal diseases.

Focusing on Patient Needs

“I am excited to contribute my expertise to Nanoscope’s mission and look forward to overseeing the development of manufacturing capabilities that will enable us to deliver these crucial therapies,” said Kaczmarek. His commitment to enhancing the manufacturing strategy aligns with Nanoscope’s goal of providing sight-restoring treatments for patients affected by conditions such as retinitis pigmentosa and other retinal degenerative diseases.

Nanoscope’s approach to treating these diseases incorporates gene-agnostic, optogenetic therapies, which offer new hope to those with limited treatment options. The company has already made significant strides, with FDA Fast Track and orphan drug designations for their leading candidates. By building robust systems for production, Kaczmarek aims to ensure that Nanoscope can meet the upcoming demand for their innovative therapies, reinforcing their position as a leader in the biotechnology field.

In conclusion, the addition of Ray Kaczmarek to the Nanoscope team illustrates a commitment to enhancing manufacturing capabilities, ensuring that the upcoming gene therapies are accessible to those in need. With experienced leadership steering the ship, Nanoscope is well-poised for success in the fast-evolving biotechnology landscape.